MOREPENLAB115.50

Morepen Laboratories Limited

· Pharma & Health
₹ CrorePeersIOLCPINNOVACAPFDCORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹6,328 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)102.72109.5895.1295.12
Receivable Days (DSO)70.1665.4367.3467.34
Payable Days (DPO)121.91132.71111.01102.13
Cash Conversion Cycle (days)50.9742.3051.4560.33
Working Capital Turnover3.472.752.682.90
Asset Turnover1.311.020.930.93
Cash Conversion (CFO/Net Income)0.760.270.340.34
CFO/EBITDA0.460.180.260.26
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.